Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Cash: 2012-2025

Historic Change in Cash for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $11.8 million.

  • Agios Pharmaceuticals' Change in Cash fell 93.00% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.0 million, marking a year-over-year decrease of 185.02%. This contributed to the annual value of -$12.0 million for FY2024, which is 76.58% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Change in Cash of $11.8 million as of Q3 2025, which was up 520.82% from $1.9 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Change in Cash high stood at $1.8 billion for Q1 2021, and its period low was -$918.9 million during Q2 2021.
  • For the 3-year period, Agios Pharmaceuticals' Change in Cash averaged around -$4.2 million, with its median value being $1.9 million (2025).
  • Within the past 5 years, the most significant YoY rise in Agios Pharmaceuticals' Change in Cash was 21,470.56% (2021), while the steepest drop was 972.85% (2021).
  • Agios Pharmaceuticals' Change in Cash (Quarterly) stood at -$197.1 million in 2021, then soared by 108.53% to $16.8 million in 2022, then spiked by 42.01% to $23.9 million in 2023, then slumped by 843.48% to -$177.5 million in 2024, then tumbled by 93.00% to $11.8 million in 2025.
  • Its Change in Cash stands at $11.8 million for Q3 2025, versus $1.9 million for Q2 2025 and $2.7 million for Q1 2025.